APO Research
Talk to an analyst

APO RESEARCH · REPORT

Choroidal Neovascularization Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Choroidal Neovascularization Drug Industry Research Report 2026

19 December 2025133 pages

Choose your research edition.

Industry ResearchChoroidal Neovascularization Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Choroidal Neovascularization Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Choroidal Neovascularization Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Choroidal Neovascularization Drug Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Choroidal Neovascularization Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Choroidal Neovascularization Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Choroidal Neovascularization Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Choroidal Neovascularization Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Choroidal Neovascularization Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Choroidal Neovascularization Drug include Eli Lilly and Company, Soligenix, Inc., RxBio, Inc., RedHill Biopharma Ltd., RDD Pharma Ltd., ProCertus BioPharm Inc., Pluristem Therapeutics Inc., PharmaIN Corporation and Onconova Therapeutics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Choroidal Neovascularization Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Choroidal Neovascularization Drug Market by Company

Eli Lilly and Company

Soligenix, Inc.

RxBio, Inc.

RedHill Biopharma Ltd.

RDD Pharma Ltd.

ProCertus BioPharm Inc.

Pluristem Therapeutics Inc.

PharmaIN Corporation

Onconova Therapeutics, Inc.

Neumedicines Inc.

Meabco A/S

INSYS Therapeutics, Inc.

Humanetics Corporation

GNI Group Ltd.

Diffusion Pharmaceuticals Inc.

Cumberland Pharmaceuticals, Inc.

Cleveland BioLabs, Inc.

Chrysalis BioTherapeutics, Inc.

Cellphire, Inc.

Choroidal Neovascularization Drug Segment by Type

EWA-001

Entolimod

DG-3

BBT-007

BB-3

AVMOC-001

Others

Choroidal Neovascularization Drug Segment by Application

Clinic

Hospital

Others

Choroidal Neovascularization Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Choroidal Neovascularization Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Choroidal Neovascularization Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Choroidal Neovascularization Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Choroidal Neovascularization Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Choroidal Neovascularization Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Choroidal Neovascularization Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Choroidal Neovascularization Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Choroidal Neovascularization Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Choroidal Neovascularization Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Choroidal Neovascularization Drug Revenue of Manufacturers (2021-2026) Table 9. Global Choroidal Neovascularization Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Choroidal Neovascularization Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Choroidal Neovascularization Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Choroidal Neovascularization Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Choroidal Neovascularization Drug, Product Type & Application Table 14. Global Choroidal Neovascularization Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Choroidal Neovascularization Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Eli Lilly and Company Company Information Table 19. Eli Lilly and Company Business Overview Table 20. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio Table 22. Eli Lilly and Company Recent Developments Table 23. Soligenix, Inc. Company Information Table 24. Soligenix, Inc. Business Overview Table 25. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio Table 27. Soligenix, Inc. Recent Developments Table 28. RxBio, Inc. Company Information Table 29. RxBio, Inc. Business Overview Table 30. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio Table 32. RxBio, Inc. Recent Developments Table 33. RedHill Biopharma Ltd. Company Information Table 34. RedHill Biopharma Ltd. Business Overview Table 35. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 37. RedHill Biopharma Ltd. Recent Developments Table 38. RDD Pharma Ltd. Company Information Table 39. RDD Pharma Ltd. Business Overview Table 40. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio Table 42. RDD Pharma Ltd. Recent Developments Table 43. ProCertus BioPharm Inc. Company Information Table 44. ProCertus BioPharm Inc. Business Overview Table 45. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio Table 47. ProCertus BioPharm Inc. Recent Developments Table 48. Pluristem Therapeutics Inc. Company Information Table 49. Pluristem Therapeutics Inc. Business Overview Table 50. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio Table 52. Pluristem Therapeutics Inc. Recent Developments Table 53. PharmaIN Corporation Company Information Table 54. PharmaIN Corporation Business Overview Table 55. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio Table 57. PharmaIN Corporation Recent Developments Table 58. Onconova Therapeutics, Inc. Company Information Table 59. Onconova Therapeutics, Inc. Business Overview Table 60. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 62. Onconova Therapeutics, Inc. Recent Developments Table 63. Neumedicines Inc. Company Information Table 64. Neumedicines Inc. Business Overview Table 65. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio Table 67. Neumedicines Inc. Recent Developments Table 68. Meabco A/S Company Information Table 69. Meabco A/S Business Overview Table 70. Meabco A/S Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Meabco A/S Choroidal Neovascularization Drug Product Portfolio Table 72. Meabco A/S Recent Developments Table 73. INSYS Therapeutics, Inc. Company Information Table 74. INSYS Therapeutics, Inc. Business Overview Table 75. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 77. INSYS Therapeutics, Inc. Recent Developments Table 78. Humanetics Corporation Company Information Table 79. Humanetics Corporation Business Overview Table 80. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio Table 82. Humanetics Corporation Recent Developments Table 83. GNI Group Ltd. Company Information Table 84. GNI Group Ltd. Business Overview Table 85. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio Table 87. GNI Group Ltd. Recent Developments Table 88. Diffusion Pharmaceuticals Inc. Company Information Table 89. Diffusion Pharmaceuticals Inc. Business Overview Table 90. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio Table 92. Diffusion Pharmaceuticals Inc. Recent Developments Table 93. Cumberland Pharmaceuticals, Inc. Company Information Table 94. Cumberland Pharmaceuticals, Inc. Business Overview Table 95. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio Table 97. Cumberland Pharmaceuticals, Inc. Recent Developments Table 98. Cleveland BioLabs, Inc. Company Information Table 99. Cleveland BioLabs, Inc. Business Overview Table 100. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio Table 102. Cleveland BioLabs, Inc. Recent Developments Table 103. Chrysalis BioTherapeutics, Inc. Company Information Table 104. Chrysalis BioTherapeutics, Inc. Business Overview Table 105. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio Table 107. Chrysalis BioTherapeutics, Inc. Recent Developments Table 108. Cellphire, Inc. Company Information Table 109. Cellphire, Inc. Business Overview Table 110. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio Table 112. Cellphire, Inc. Recent Developments Table 113. Global Choroidal Neovascularization Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Choroidal Neovascularization Drug Sales by Region (2021-2026) & (K Units) Table 115. Global Choroidal Neovascularization Drug Sales Market Share by Region (2021-2026) Table 116. Global Choroidal Neovascularization Drug Sales by Region (2027-2032) & (K Units) Table 117. Global Choroidal Neovascularization Drug Sales Market Share by Region (2027-2032) Table 118. Global Choroidal Neovascularization Drug Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2021-2026) Table 120. Global Choroidal Neovascularization Drug Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2027-2032) Table 122. North America Choroidal Neovascularization Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 124. North America Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 125. North America Choroidal Neovascularization Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Choroidal Neovascularization Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Choroidal Neovascularization Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 129. Europe Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 130. Europe Choroidal Neovascularization Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Choroidal Neovascularization Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Choroidal Neovascularization Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific Choroidal Neovascularization Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Choroidal Neovascularization Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Choroidal Neovascularization Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 139. South America Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 140. South America Choroidal Neovascularization Drug Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Choroidal Neovascularization Drug Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Choroidal Neovascularization Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Units) Table 148. Global Choroidal Neovascularization Drug Sales by Type (2027-2032) & (K Units) Table 149. Global Choroidal Neovascularization Drug Sales Market Share by Type (2021-2026) Table 150. Global Choroidal Neovascularization Drug Sales Market Share by Type (2027-2032) Table 151. Global Choroidal Neovascularization Drug Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Choroidal Neovascularization Drug Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2021-2026) Table 154. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2027-2032) Table 155. Global Choroidal Neovascularization Drug Price by Type (2021-2026) & (US$/Unit) Table 156. Global Choroidal Neovascularization Drug Price by Type (2027-2032) & (US$/Unit) Table 157. Global Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Units) Table 158. Global Choroidal Neovascularization Drug Sales by Application (2027-2032) & (K Units) Table 159. Global Choroidal Neovascularization Drug Sales Market Share by Application (2021-2026) Table 160. Global Choroidal Neovascularization Drug Sales Market Share by Application (2027-2032) Table 161. Global Choroidal Neovascularization Drug Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Choroidal Neovascularization Drug Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2021-2026) Table 164. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2027-2032) Table 165. Global Choroidal Neovascularization Drug Price by Application (2021-2026) & (US$/Unit) Table 166. Global Choroidal Neovascularization Drug Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Choroidal Neovascularization Drug Distributors List Table 170. Choroidal Neovascularization Drug Customers List Table 171. Choroidal Neovascularization Drug Industry Trends Table 172. Choroidal Neovascularization Drug Industry Drivers Table 173. Choroidal Neovascularization Drug Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Choroidal Neovascularization Drug Product Image Figure 5. Global Choroidal Neovascularization Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Choroidal Neovascularization Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Choroidal Neovascularization Drug Sales (2021-2032) & (K Units) Figure 8. Global Choroidal Neovascularization Drug Average Price (US$/Unit) & (2021-2032) Figure 9. EWA-001 Product Image Figure 10. Entolimod Product Image Figure 11. DG-3 Product Image Figure 12. BBT-007 Product Image Figure 13. BB-3 Product Image Figure 14. AVMOC-001 Product Image Figure 15. Others Product Image Figure 16. Clinic Product Image Figure 17. Hospital Product Image Figure 18. Others Product Image Figure 19. Global Choroidal Neovascularization Drug Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Choroidal Neovascularization Drug, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Choroidal Neovascularization Drug Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Choroidal Neovascularization Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Choroidal Neovascularization Drug Sales by Region in 2025 Figure 25. Global Choroidal Neovascularization Drug Revenue by Region in 2025 Figure 26. North America Choroidal Neovascularization Drug Market Size by Country in 2025 Figure 27. North America Choroidal Neovascularization Drug Sales Market Share by Country (2021-2032) Figure 28. North America Choroidal Neovascularization Drug Revenue Market Share by Country (2021-2032) Figure 29. United States Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Choroidal Neovascularization Drug Market Size by Country in 2025 Figure 32. Europe Choroidal Neovascularization Drug Sales Market Share by Country (2021-2032) Figure 33. Europe Choroidal Neovascularization Drug Revenue Market Share by Country (2021-2032) Figure 34. Germany Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Choroidal Neovascularization Drug Market Size by Country in 2025 Figure 40. Asia Pacific Choroidal Neovascularization Drug Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Choroidal Neovascularization Drug Revenue Market Share by Country (2021-2032) Figure 42. China Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. China Taiwan Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Choroidal Neovascularization Drug Market Size by Country in 2025 Figure 51. South America Choroidal Neovascularization Drug Sales Market Share by Country (2021-2032) Figure 52. South America Choroidal Neovascularization Drug Revenue Market Share by Country (2021-2032) Figure 53. Mexico Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Brazil Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Choroidal Neovascularization Drug Market Size by Country in 2025 Figure 57. Middle East and Africa Choroidal Neovascularization Drug Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Choroidal Neovascularization Drug Revenue Market Share by Country (2021-2032) Figure 59. Turkey Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. UAE Choroidal Neovascularization Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Global Choroidal Neovascularization Drug Sales Market Share by Type (2021-2032) Figure 63. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2021-2032) Figure 64. Global Choroidal Neovascularization Drug Price (US$/Unit) by Type (2021-2032) Figure 65. Global Choroidal Neovascularization Drug Sales Market Share by Application (2021-2032) Figure 66. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2021-2032) Figure 67. Global Choroidal Neovascularization Drug Price (US$/Unit) by Application (2021-2032) Figure 68. Choroidal Neovascularization Drug Value Chain Figure 69. Choroidal Neovascularization Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Choroidal Neovascularization Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • EWA-001
  • Entolimod
  • DG-3
  • BBT-007
  • BB-3
  • AVMOC-001
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Eli Lilly and Company
  • Soligenix, Inc.
  • RxBio, Inc.
  • RedHill Biopharma Ltd.
  • RDD Pharma Ltd.
  • ProCertus BioPharm Inc.
  • Pluristem Therapeutics Inc.
  • PharmaIN Corporation
  • Onconova Therapeutics, Inc.
  • Neumedicines Inc.
  • Meabco A/S
  • INSYS Therapeutics, Inc.
  • Humanetics Corporation
  • GNI Group Ltd.
  • Diffusion Pharmaceuticals Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cleveland BioLabs, Inc.
  • Chrysalis BioTherapeutics, Inc.
  • Cellphire, Inc.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Choroidal Neovascularization Drug Market Size (2021-2032)
  4. 2.2.2 Global Choroidal Neovascularization Drug Sales (2021-2032)
  5. 2.2.3 Global Choroidal Neovascularization Drug Market Average Price (2021-2032)
  6. 2.3 Choroidal Neovascularization Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 EWA-001
  9. 2.3.3 Entolimod
  10. 2.3.4 DG-3
  11. 2.3.5 BBT-007
  12. 2.3.6 BB-3
  13. 2.3.7 AVMOC-001
  14. 2.3.8 Others
  15. 2.4 Choroidal Neovascularization Drug by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 Clinic
  18. 2.4.3 Hospital
  19. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Choroidal Neovascularization Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Choroidal Neovascularization Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Choroidal Neovascularization Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Choroidal Neovascularization Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Choroidal Neovascularization Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Choroidal Neovascularization Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Choroidal Neovascularization Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Choroidal Neovascularization Drug, Established Date
  9. 3.9 Global Choroidal Neovascularization Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Eli Lilly and Company
  2. 4.1.1 Eli Lilly and Company Company Information
  3. 4.1.2 Eli Lilly and Company Business Overview
  4. 4.1.3 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Eli Lilly and Company Choroidal Neovascularization Drug Product Portfolio
  6. 4.1.5 Eli Lilly and Company Recent Developments
  7. 4.2 Soligenix, Inc.
  8. 4.2.1 Soligenix, Inc. Company Information
  9. 4.2.2 Soligenix, Inc. Business Overview
  10. 4.2.3 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Soligenix, Inc. Choroidal Neovascularization Drug Product Portfolio
  12. 4.2.5 Soligenix, Inc. Recent Developments
  13. 4.3 RxBio, Inc.
  14. 4.3.1 RxBio, Inc. Company Information
  15. 4.3.2 RxBio, Inc. Business Overview
  16. 4.3.3 RxBio, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 RxBio, Inc. Choroidal Neovascularization Drug Product Portfolio
  18. 4.3.5 RxBio, Inc. Recent Developments
  19. 4.4 RedHill Biopharma Ltd.
  20. 4.4.1 RedHill Biopharma Ltd. Company Information
  21. 4.4.2 RedHill Biopharma Ltd. Business Overview
  22. 4.4.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  24. 4.4.5 RedHill Biopharma Ltd. Recent Developments
  25. 4.5 RDD Pharma Ltd.
  26. 4.5.1 RDD Pharma Ltd. Company Information
  27. 4.5.2 RDD Pharma Ltd. Business Overview
  28. 4.5.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Product Portfolio
  30. 4.5.5 RDD Pharma Ltd. Recent Developments
  31. 4.6 ProCertus BioPharm Inc.
  32. 4.6.1 ProCertus BioPharm Inc. Company Information
  33. 4.6.2 ProCertus BioPharm Inc. Business Overview
  34. 4.6.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product Portfolio
  36. 4.6.5 ProCertus BioPharm Inc. Recent Developments
  37. 4.7 Pluristem Therapeutics Inc.
  38. 4.7.1 Pluristem Therapeutics Inc. Company Information
  39. 4.7.2 Pluristem Therapeutics Inc. Business Overview
  40. 4.7.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product Portfolio
  42. 4.7.5 Pluristem Therapeutics Inc. Recent Developments
  43. 4.8 PharmaIN Corporation
  44. 4.8.1 PharmaIN Corporation Company Information
  45. 4.8.2 PharmaIN Corporation Business Overview
  46. 4.8.3 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 PharmaIN Corporation Choroidal Neovascularization Drug Product Portfolio
  48. 4.8.5 PharmaIN Corporation Recent Developments
  49. 4.9 Onconova Therapeutics, Inc.
  50. 4.9.1 Onconova Therapeutics, Inc. Company Information
  51. 4.9.2 Onconova Therapeutics, Inc. Business Overview
  52. 4.9.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  54. 4.9.5 Onconova Therapeutics, Inc. Recent Developments
  55. 4.10 Neumedicines Inc.
  56. 4.10.1 Neumedicines Inc. Company Information
  57. 4.10.2 Neumedicines Inc. Business Overview
  58. 4.10.3 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Neumedicines Inc. Choroidal Neovascularization Drug Product Portfolio
  60. 4.10.5 Neumedicines Inc. Recent Developments
  61. 4.11 Meabco A/S
  62. 4.11.1 Meabco A/S Company Information
  63. 4.11.2 Meabco A/S Business Overview
  64. 4.11.3 Meabco A/S Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Meabco A/S Choroidal Neovascularization Drug Product Portfolio
  66. 4.11.5 Meabco A/S Recent Developments
  67. 4.12 INSYS Therapeutics, Inc.
  68. 4.12.1 INSYS Therapeutics, Inc. Company Information
  69. 4.12.2 INSYS Therapeutics, Inc. Business Overview
  70. 4.12.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  72. 4.12.5 INSYS Therapeutics, Inc. Recent Developments
  73. 4.13 Humanetics Corporation
  74. 4.13.1 Humanetics Corporation Company Information
  75. 4.13.2 Humanetics Corporation Business Overview
  76. 4.13.3 Humanetics Corporation Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Humanetics Corporation Choroidal Neovascularization Drug Product Portfolio
  78. 4.13.5 Humanetics Corporation Recent Developments
  79. 4.14 GNI Group Ltd.
  80. 4.14.1 GNI Group Ltd. Company Information
  81. 4.14.2 GNI Group Ltd. Business Overview
  82. 4.14.3 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 GNI Group Ltd. Choroidal Neovascularization Drug Product Portfolio
  84. 4.14.5 GNI Group Ltd. Recent Developments
  85. 4.15 Diffusion Pharmaceuticals Inc.
  86. 4.15.1 Diffusion Pharmaceuticals Inc. Company Information
  87. 4.15.2 Diffusion Pharmaceuticals Inc. Business Overview
  88. 4.15.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product Portfolio
  90. 4.15.5 Diffusion Pharmaceuticals Inc. Recent Developments
  91. 4.16 Cumberland Pharmaceuticals, Inc.
  92. 4.16.1 Cumberland Pharmaceuticals, Inc. Company Information
  93. 4.16.2 Cumberland Pharmaceuticals, Inc. Business Overview
  94. 4.16.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product Portfolio
  96. 4.16.5 Cumberland Pharmaceuticals, Inc. Recent Developments
  97. 4.17 Cleveland BioLabs, Inc.
  98. 4.17.1 Cleveland BioLabs, Inc. Company Information
  99. 4.17.2 Cleveland BioLabs, Inc. Business Overview
  100. 4.17.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product Portfolio
  102. 4.17.5 Cleveland BioLabs, Inc. Recent Developments
  103. 4.18 Chrysalis BioTherapeutics, Inc.
  104. 4.18.1 Chrysalis BioTherapeutics, Inc. Company Information
  105. 4.18.2 Chrysalis BioTherapeutics, Inc. Business Overview
  106. 4.18.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product Portfolio
  108. 4.18.5 Chrysalis BioTherapeutics, Inc. Recent Developments
  109. 4.19 Cellphire, Inc.
  110. 4.19.1 Cellphire, Inc. Company Information
  111. 4.19.2 Cellphire, Inc. Business Overview
  112. 4.19.3 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Cellphire, Inc. Choroidal Neovascularization Drug Product Portfolio
  114. 4.19.5 Cellphire, Inc. Recent Developments
5 Global Choroidal Neovascularization Drug Market Scenario by Region
  1. 5.1 Global Choroidal Neovascularization Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Choroidal Neovascularization Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Choroidal Neovascularization Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Choroidal Neovascularization Drug Sales by Region: 2027-2032
  5. 5.3 Global Choroidal Neovascularization Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Choroidal Neovascularization Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Choroidal Neovascularization Drug Revenue by Region: 2027-2032
  8. 5.4 North America Choroidal Neovascularization Drug Market Facts & Figures by Country
  9. 5.4.1 North America Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Choroidal Neovascularization Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Choroidal Neovascularization Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Choroidal Neovascularization Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Choroidal Neovascularization Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Choroidal Neovascularization Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Choroidal Neovascularization Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Choroidal Neovascularization Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Choroidal Neovascularization Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Choroidal Neovascularization Drug Market Facts & Figures by Country
  35. 5.7.1 South America Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Choroidal Neovascularization Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Choroidal Neovascularization Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Choroidal Neovascularization Drug Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Choroidal Neovascularization Drug Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Choroidal Neovascularization Drug Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Choroidal Neovascularization Drug Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Choroidal Neovascularization Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Choroidal Neovascularization Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Choroidal Neovascularization Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Choroidal Neovascularization Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Choroidal Neovascularization Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Choroidal Neovascularization Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Choroidal Neovascularization Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Choroidal Neovascularization Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Choroidal Neovascularization Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Choroidal Neovascularization Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Choroidal Neovascularization Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Choroidal Neovascularization Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Choroidal Neovascularization Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Choroidal Neovascularization Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Choroidal Neovascularization Drug Value Chain Analysis
  2. 8.1.1 Choroidal Neovascularization Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Choroidal Neovascularization Drug Production Mode & Process
  5. 8.2 Choroidal Neovascularization Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Choroidal Neovascularization Drug Distributors
  8. 8.2.3 Choroidal Neovascularization Drug Customers
9 Global Choroidal Neovascularization Drug Analyzing Market Dynamics
  1. 9.1 Choroidal Neovascularization Drug Industry Trends
  2. 9.2 Choroidal Neovascularization Drug Industry Drivers
  3. 9.3 Choroidal Neovascularization Drug Industry Opportunities and Challenges
  4. 9.4 Choroidal Neovascularization Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst